Subcortical Dice lower bound
0.89 Dice coefficient, lower endpoint of reported range
- EndpointSegmentation overlap
- Population71-subject accuracy cohort within the FDA ANDI validation
- Tested versionANDI 2.0 configuration submitted in K252298
FDA-cleared profile
Imeka Solutions, Inc. · MRI · FDA-cleared (510(k))
Authorized purpose: Adjunctive quantitative brain MRI analysis that compares patient measures with normative and longitudinal references; a physician reviews all results and makes the clinical decision.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: Adjunctive quantitative brain MRI analysis that compares patient measures with normative and longitudinal references; a physician reviews all results and makes the clinical decision.
Evidence takeaway. Evidence from the reviewed source record: FDA validation included 747 independent validation subjects across sites and manufacturers. The detailed accuracy cohort included 71 subjects with healthy, MS, Parkinson, Alzheimer and MCI cases; subcortical Dice averaged 0.89-0.96 and cortical Dice 0.79-0.93. Reproducibility testing in 59 subjects reported mean absolute volume difference 2.1% and individual differences 1.2%-3.9%.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
The cleared endpoints are segmentation and volumetric agreement measures, not disease-detection sensitivity.
The cleared endpoints are segmentation and volumetric agreement measures, not disease-detection specificity.
0.89 Dice coefficient, lower endpoint of reported range
0.96 Dice coefficient, upper endpoint of reported range
0.79 Dice coefficient, lower endpoint of reported range
0.93 Dice coefficient, upper endpoint of reported range
2.1 percent
1.2 percent, lower endpoint of reported range
3.9 percent, upper endpoint of reported range
K252298
The 71-subject detailed cohort included 35 women and 36 men, ages 18-86, with the disease mix stated in the FDA summary.
K252298
FDA reports mean absolute volume difference 2.1% and individual differences 1.2%-3.9%.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
The downloaded exact-ID recall packet contained zero records; this limited result does not establish absence of recall or safety information.
Price not public here; enter your quote
Not verified: Pricing information is recorded but not verified against a resolving source.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: DICOM brain MR image sets including DWI and T1 sequences within the supported acquisition and scanner scope.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-07 · FDA 510(k) K252298: ANDI 2.0
Source context, not route validation: The FDA summary describes cloud or on-premises SaaS processing without a GUI and generation of reports for clinical review; local DICOM routing and viewer configuration require confirmation.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-07 · FDA 510(k) K252298: ANDI 2.0
Source context, not route validation: Cloud or on-premises SaaS deployment described in the submission; no standalone GUI is described.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-07 · FDA 510(k) K252298: ANDI 2.0
Source context, not route validation: Atlas-assisted visualization, automated segmentation and volumes, normative comparison and longitudinal reports for white-matter microstructure and optional gray-matter volumetry.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-07 · FDA 510(k) K252298: ANDI 2.0
Unresolved route: Atlas-assisted visualization, automated segmentation and volumes, normative comparison and longitudinal reports for white-matter microstructure and optional gray-matter volumetry.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-07 · FDA 510(k) K252298: ANDI 2.0
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
This family statement does not establish exact K252298 controls, retention, certification or a site-specific security assessment.
The cleared submission describes cloud or on-premises SaaS processing without a GUI and generation of quantitative brain MRI reports.
exact submission · checked 2026-09-07Imeka describes ANDI as a secure-cloud workflow with a 5-8 minute single-shell sequence, support for MRI manufacturers at 1.5T or 3T, 33 fiber-tract segmentations, normative comparison and longitudinal reports.
product family · checked 2026-09-06Family page capabilities do not establish exact K252298 availability, hosting contract or performance.
Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
Stored candidate metadata was screened; no PubMed or trial IDs were returned for this submission. This is not a full-paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, vendor announcement, stored candidate metadata, literature index, trial registry, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
No public price or quote for ANDI 2.0 was reviewed.
License, per-study, subscription and implementation terms were not established.
Bounded web search on 2026-10-26 (query: "Imeka ANDI reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. Only trade press (BioWorld, 2023-08-24) mentions new CPT Category III codes for quantitative brain MRI; no vendor or payer page names a code for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
8 sources - 3 history items
Scope: identity, purpose, clinicalUse, modality, anatomy, workflowRole, intendedUsers, careSetting, input, output, limitations, integration, deployment, evidenceMetrics, evidenceStudies
Scope: regulatoryIdentity, modalityContext
Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: recallDiscovery, nativeSubmissionMatching
Scope: productFamilyContext, clinicalUse, implementationCapabilities
Scope: productVersion, productFamilyContext
Regulatory record
510(k)
Research record
fda record reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Imeka Solutions, Inc.
Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.
BeauBrain Healthcare, Inc.
Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
Siemens Healthcare GmbH
Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.
AIRS Medical Inc.
Authorized purpose: Adjunctive brain MRI morphometry and lesion-quantification support for qualified healthcare professionals, including segmented overlays, volumetric measurements, normative percentiles and longitudinal comparison.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history